Innovations in diagnostic imaging of localized prostate cancer

Pummer, Karl; Rieken, Malte; Augustin, Herbert; Gutschi, T.; Shariat, Shahrokh F.

doi:10.1007/s00345-013-1172-6

Cited by 28 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 12 systematic reviews [11][12][13][14][15][16][17][18][19][20][21][22] were relevant and met the preplanned inclusion criteria; however, none of them covered both of the guideline objectives or used the same study selection criteria as ours. A total of 8663 original studies in English were identified and 15 were analyzed.…”

Section: Literature Search Resultsmentioning

confidence: 99%

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Haider

Yao

Loblaw

et al. 2017

CUAJ

View full text Add to dashboard Cite

Cite as: Can Urol Assoc J 2017;11(1-2):E1-7. http://dx.doi.org/10.5489/cuaj.3968 Published online January 12, 2017 AbstractThis clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy.

show abstract

Section: Literature Search Resultsmentioning

confidence: 99%

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Haider

Yao

Loblaw

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…But its availability, costs, and the possibility to repeat the examination whenever necessary make it an asset for the urologist. A number of techniques have been developed in order to improve the sensitivity and specificity of grey scale US and they have proven their advantages in terms of PCa detection rate and the guidance of prostate biopsy [15]. Multiparametric MRI has revolutionized the diagnostics of PCa and offered the possibility to perform a true targeted biopsy, but the costs of the investigation, the low volume centers, and the lack of specialists hinder its implementation [12].…”

Section: Discussionmentioning

confidence: 99%

“…The suspicion is raised by the presence of a hypoechoic area, but this appearance is characteristic only for about 60% of PCa. The rest of PCa nodules are isoechoic, therefore they are usually missedat US [15,16]. Furthermore, only 17-57% of the hypoechoic areas at greyscale US are diagnosed as malignant at biopsy [17].…”

Section: Conventional Transrectal Grey Scale Ultrasoundmentioning

confidence: 99%

Prostate ultrasound: back in business!

et al. 2017

View full text Add to dashboard Cite

The use of grey scale prostate ultrasound decreased after the implementation of magnetic resonance imaging (MRI) for the diagnosis and evaluation of prostate cancer. The new developments, such as multiparametric ultrasound and MRI-ultrasound fusion technology, renewed the interest for this imaging method in the assessment of prostate cancer. The purpose of this paper was to review the current role of prostate ultrasound in the setting of these new applications. A thorough reevaluation of the selection criteria of the patients is required to assess which patients would benefit from multiparametric ultrasound, who wouldbenefit from multiparametric MRI or the combination of both to assist prostate biopsy in order to ensure the balance between overdiagnosis and underdiagnosis of prostate cancer.

show abstract

“…In spite of the advances in prostate cancer (PCa) detection and treatment, PCa continues to be one of the leading causes of cancer-related mortality in men [1], with approximately 180,000 new cases diagnosed and 26,000 cancer-related deaths projected in the United States in 2016 [2]. Hence, the diagnostic accuracy is essential to early intervention regarding tumor progression and metastasis, leading to increasing opportunity for surgery and satisfied prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…Most prostate neoplasms (about 60%-80%) are hypoechoic on grey-scale TRUS, whereas 30%-40% are isoechoic, and approximately 1.5% are hyper-echoic [2]. The sensitivity and specificity of ultrasound for PCa diagnosis vary considerably from 18% to 96% and from 46% to 91% [1]. Considering the effectiveness and drawbacks of ultrasound, to develop a new protocol is necessary.…”

Section: Introductionmentioning

confidence: 99%

Real-Time Elastography in the diagnosis of prostate cancer: a systematic review

Zhang

Meng

et al. 2019

Med Ultrason

View full text Add to dashboard Cite

Aim: To evaluate the diagnostic accuracy of real-time elastography as a method for detecting prostate cancer.Material and methods: Relevant studies applying real-time elastography as the diagnostic modality and biopsy as the reference standard, published by March 1, 2018 were retrieved from PubMed, EMBASE, Web of Science and Cochrane Library databases. Two independent reviewers inspected all these articles to confirm the matching of the inclusion criteria. One reviewer with methodological expertise extracted the data from the included studies. Sensitivity, specificity and diagnostic odds ratio (DOR) were used to obtain overall estimates. Randomized effect method, meta-regression and subgroup analysis were performed.Results: Twenty-four studies out of 1156 identified articles met the inclusion criteria. Three groups were set: analysisby patient (Group 1), by core (Group 2), and by image (Group 3) and subgroups set in Group 1. The pooled estimate ofreal-time elastography sensitivity/ specificity/ DOR calculated with the identical P-value 0.00. Within subgroups “Asia” and“PSA>=10 ng/ml”, the pooled sensitivity, specificity and DOR were 0.83, 0.65 (p=0.01, I2=73.40%; p=0.02, I2=69.5%), 0.80, 0.82 (p=0.66, I2=0.00%; p=0.58, I2=0.00%) and 20.2, 8.67 (p=0.09, I2=54.2%; p=0.20, I2=35.5%), respectively. In these three groups, the areas under the SROC curve were 0.7417, 0.9246, and 0.6213 independently.Conclusions: Real-time elastography is a promising, reliable modality for the non-invasive diagnosis of patients with prostate cancer. The diagnostic accuracy of real-time elastography correlates tightly to the presence of higher PSA level and may help avoid unnecessary biopsy. It seems to be a useful tool in systemic biopsy.

show abstract

Innovations in diagnostic imaging of localized prostate cancer

Cited by 28 publications

References 47 publications

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Prostate ultrasound: back in business!

Real-Time Elastography in the diagnosis of prostate cancer: a systematic review

Contact Info

Product

Resources

About